RightFit Trial Directory

Lung Cancer clinical trials in Tyler, TX

15 recruiting lung cancer studies with a site in Tyler, TX.

All trials in Tyler, TX · All Lung Cancer trials

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · Houston, TX · +51 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Austin, TX · Tyler, TX · +18 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +238 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +223 more sites

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Abilene, TX · Austin, TX · Dallas, TX · +34 more sites

RecruitingPhase 1 / Phase 2NCT06996782

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Sponsor: AstraZeneca

Tyler, TX · +9 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Amarillo, TX · Austin, TX · Denton, TX · +35 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Abilene, TX · Harlingen, TX · Houston, TX · +53 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Abilene, TX · Austin, TX · Dallas, TX · +94 more sites

RecruitingPhase 1NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Sponsor: Bristol-Myers Squibb

Dallas, TX · Fort Worth, TX · Houston, TX · +22 more sites

RecruitingPhase 1 / Phase 2NCT06892548

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Sponsor: BioNTech SE

Dallas, TX · Houston, TX · Tyler, TX · +14 more sites

RecruitingPhase 3NCT06801834

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Sponsor: Gilead Sciences

Abilene, TX · Houston, TX · New Braunfels, TX · +20 more sites

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Houston, TX · Tyler, TX · +27 more sites

RecruitingPhase 1NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Houston, TX · +103 more sites

RecruitingPhase 1NCT06069570

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases

Sponsor: Kiromic BioPharma Inc.

Tyler, TX · +4 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.